Clinical Trial Update: Olmesartan Medoxomil and Diabetic Nephropathy [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Olmesartan Medoxomil for diabetic nephropathy in type 2 diabetes has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Nephropathy
• Proteinuria
• Renal Disease
• Type 2 Diabetes Mellitus

Drugs mentioned

• OLMESARTAN MEDOXOMIL (olmesartan medoxomil)

Snippet

Sponsor: Sankyo Pharma Gmbh | Conditions: Type 2 Diabetes Mellitus, Diabetic Nephropathy | Phase 3 | Status: COMPLETED